https://www.pharmaceutical-technology.com/news/merck-partners-with-hibercell-for-phase-ib-renal-carcinoma-trial/
Merck partners with HiberCell for Phase Ib renal carcinoma trial
Dec 6, 2023 - The Phase Ib trial will evaluate the combination therapy of Welireg and HC-7366 in patients with clear cell renal cell carcinoma.
phase ibrenal carcinomamerckpartnerstrial
https://www.biospace.com/kangpu-biopharmaceuticals-initiates-phase-ib-iia-clinical-trial-of-kpg-818-in-systemic-lupus-erythematosus
Kangpu Biopharmaceuticals Initiates Phase Ib/IIa Clinical Trial of KPG-818 in Systemic Lupus...
Nov 17, 2020 - Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China , announced that, after consulting with the U.S. Food and Drug Administration...
https://www.biospace.com/77-4-percent-orr-abbisko-to-present-the-updated-clinical-phase-ib-data-of-pimicotinib-absk021-at-the-2023-asco-annual-meeting
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the...
May 29, 2023 - Abbisko Therapeutics Co., Ltd. announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib in treating patients with advanced...
https://www.biospace.com/trovagene-announces-activation-of-two-additional-clinical-trial-sites-to-conduct-its-phase-1b-2-study-of-pcm-075-in-patients-with-aml
Trovagene Announces Activation of Two Additional Clinical Trial Sites to Conduct its Phase Ib/II...
Feb 13, 2018 - The trial, which is being led by hematologist Jorge Cortes, M.D., Deputy Department Chair, Department of Leukemia, Division of Cancer Medicine, The University...
https://www.biospace.com/press-releases/oryzon-announces-first-patient-dosed-in-an-investigator-initiated-phase-ib-study-of-iadademstat-in-first-line-acute-myeloid-leukemia
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in...
https://www.dana-farber.org/clinical-trials/13-505
An open label, two-part, phase Ib/II study to investigate the safety, pharmacokinetics,...
This phase Ib/II trial studies the side effects and best dose of trametinib and navitoclax and how well they work in treating patients with solid tumors that...
https://www.biospace.com/press-releases/heparegenix-doses-first-patient-in-phase-ib-trial-with-small-molecule-inhibitor-hrx-215-to-promote-liver-regeneration
HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote...
https://www.dana-farber.org/clinical-trials/20-127
A PHASE IB/II STUDY OF APG-2575 AS A SINGLE AGENT OR IN COMBINATION WITH OTHER THERAPEUTIC AGENTS...
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of...
https://www.businesswire.com/news/home/20210818005763/en/Scioto-Biosciences-Inc.-Announces-First-Patient-Dosed-in-Phase-Ib-Study-in-Patients-Diagnosed-with-Autistic-Disorder
Scioto Biosciences, Inc. Announces First Patient Dosed in Phase Ib Study in Patients Diagnosed with...
Scioto Biosciences announces first patient dosed in Phase Ib trial in patients diagnosed with Autistic Disorder.
https://www.prnewswire.com/news-releases/airway-therapeutics-gibt-die-verabreichung-von-at-100-beim-ersten-patienten-in-der-phase-ib-studie-bei-fruhgeborenen-mit-risiko-fur-bronchopulmonale-dysplasie-bpd-bekannt-817341391.html
Airway Therapeutics gibt die Verabreichung von AT-100 beim ersten Patienten in der Phase Ib-Studie...
/PRNewswire/ -- Airway Therapeutics Inc. (Airway), ein biopharmazeutisches Unternehmen, das eine neue Klasse von Biologika entwickelt, um den Kreislauf von...
https://www.biospace.com/prescient-therapeutics-release-fda-allows-ptx-ind-for-leukemia-phase-ib-and-ii-trials
Prescient Therapeutics Release: FDA Allows PTX IND For Leukemia Phase Ib & II Trials - BioSpace
https://www.biospace.com/harbour-biomed-announces-results-of-phase-ib-clinical-trial-of-porustobart-in-combination-with-toripalimab-in-advanced-high-grade-neuroendocrine-neoplasms-at-aacr-annual-meeting
Harbour BioMed Announces Results of Phase Ib Clinical Trial of Porustobart in Combination with...
Apr 14, 2023 - Harbour BioMed today announced that the results of its phase Ib clinical trial of porustobart (HBM4003) in combination of toripalimab in patients with advanced...
https://www.acsh.org/news/2019/04/17/hurdle-no-hurl-vaxart-starts-phase-ib-norovirus-vaccine-trials-13965
Hurdle But No Hurl: Vaxart Starts Phase Ib Norovirus Vaccine Trials | American Council on Science...
Vaxart Inc., a San Francisco based vaccine biotech, just announced that it will begin dosing subjects in a Phase 1b study company's bivalent oral experimental...
https://www.biospace.com/press-releases/ascletis-announces-positive-interim-results-from-its-u-s-phase-ib-trial-with-asc30-a-potentially-first-in-class-subcutaneous-injection-small-molecule-glp-1r-agonist
Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially...
https://www.businesswire.com/news/home/20220526005245/en/Scioto-Biosciences-Inc.-Announces-Top-Line-Results-of-SB-121-in-a-Phase-Ib-Trial-in-Patients-Diagnosed-With-Autism-Spectrum-Disorder
Scioto Biosciences, Inc. Announces Top-Line Results of SB-121 in a Phase Ib Trial in Patients...
Scioto Biosciences announced top-line results of its Phase Ib trial of lead asset, SB-121, in patients diagnosed with autism spectrum disorder.
https://www.news-medical.net/news/20260421/Last-patient-has-completed-AlzeCures-Phase-Ib-clinical-study-with-NeuroRestore-ACD856.aspx
Last patient has completed AlzeCure's Phase Ib clinical study with NeuroRestore ACD856
Apr 21, 2026 - AlzeCure Pharma AB (publ), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain,...